more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$18.95 USD

+0.51 (2.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $18.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What to Expect From Epizyme (EPZM) This Earnings Season?

by Zacks Equity Research Published on October 27,2017

Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate, tazemetostat.

Allergan (AGN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research Published on October 26,2017

While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.

Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus

by Zacks Equity Research Published on October 26,2017

Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.

Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research Published on October 23,2017

Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.

Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?

by Zacks Equity Research Published on October 20,2017

Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.

AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

by Zacks Equity Research Published on October 19,2017

AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca

by Zacks Equity Research Published on October 10,2017

Clovis submitted a sNDA to the FDA for expansion of Rubraca's label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.

Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher

by Zacks Equity Research Published on September 19,2017

Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.

TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion

by Zacks Equity Research Published on September 18,2017

TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.

Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?

by Zacks Equity Research Published on September 07,2017

Clovis (CLVS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

CLVSPositive Net Change

Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal

by Zacks Equity Research Published on August 30,2017

Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.

Here's Why Clovis Stock Is Up Almost 60% So Far in 2017

by Zacks Equity Research Published on August 23,2017

Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.

AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

by Zacks Equity Research Published on August 18,2017

AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.

Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses

by Zacks Equity Research Published on August 15,2017

Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.

Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses

by Zacks Equity Research Published on August 03,2017

Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.

What's in the Cards for Merrimack (MACK) in Q2 Earnings?

by Zacks Equity Research Published on July 28,2017

Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.

What's in the Cards for Aerie (AERI) This Earnings Season?

by Zacks Equity Research Published on July 27,2017

Aerie Pharmaceuticals (AERI) is expected to throw light on updates on Rhopressa during its second-quarter earnings call on Aug 1.

Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?

by Zacks Equity Research Published on July 27,2017

BioMarin Pharmaceutical Inc. (BMRN) is likely to see continued momentum in Vimizim and Kuvan sales backed by robust patient growth in Q2.

What's in Store for Endocyte (ECYT) this Earnings Season?

by Zacks Equity Research Published on July 26,2017

Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.

AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

by Zacks Equity Research Published on July 26,2017

AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.

What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

by Zacks Equity Research Published on July 24,2017

Merck KGaA???s (MKGAF) Life Science segment is expected to perform well following the approval of Bavencio.

Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

by Zacks Equity Research Published on July 13,2017

We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

Healthcare ETF (IYH) Hits New 52-Week High

by Sweta Killa Published on June 23,2017

This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?